Crocus Technology, a leading developer of TMR magnetic sensor technology and embedded MRAM, today announced that it has licensed advanced magnetic TMR technology to NXP Semiconductors, the global leader in automotive semiconductor solutions. TMR will help enable the next generation … Continued
Muse bio, a privately-held company leading the development of next-generation genome engineering capabilities, today announced Dr. John Stuelpnagel, co-founder, first CEO and former COO of Illumina and a well-known genomics industry entrepreneur, will become Chairman of Muse bio’s Board of … Continued
Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses, today announced that it has licensed LMB-100, a next-generation immunotoxin, from the Center for Cancer Research (CCR) at the NCI, part … Continued
Twist Bioscience, a company accelerating science and innovation through rapid, high-quality DNA synthesis, today announced the appointment of Mark Daniels to the newly-created position of chief ethics and compliance officer. Mr. Daniels will maintain his current position as Twist Bioscience’s … Continued
ARMO BioSciences, Inc., a late-stage immuno-oncology company, today announced the appointment of Pierre Legault to its Board of Directors. Mr. Legault will serve as Chairman of the Audit Committee. “Pierre is an experienced executive and board member who has extensive knowledge … Continued
Emulate, Inc. announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Food and Drug Administration’s (FDA) Office of Foods and Veterinary Medicine. Under this multi-year CRADA, Emulate and FDA will collaborate to … Continued
Twist Bioscience, a company accelerating science and innovation through rapid, high-quality DNA synthesis, today announced that it raised an additional $33 million. To date, Twist Bioscience has raised a total of $166 million. “It is an exciting time to be … Continued
Muse bio, a privately-held company leading the development of next-generation genome engineering capabilities, today announced the completion of a $23 million Series B financing. The oversubscribed financing was led by Venrock and included investments from Foresite Capital and Paladin Capital … Continued
Tarveda Therapeutics, Inc. a clinical-stage biopharmaceutical company discovering and developing Pentarins™ as a new class of potent and selective cancer medicines, today announced the completion of a $30 million Series D equity financing. The round was led by new investor Versant … Continued
Emulate Inc. announced today that its Organs-on-Chips technology has expanded functionality to model viral infection in a human-relevant system, opening new opportunities for studying infectious diseases and better predicting human responses to new medicines. The new applications are based on … Continued
Twist Bioscience, a company accelerating science and innovation through rapid, high-quality DNA synthesis on silicon, today announced that it is now shipping genes up to 3,200 base pairs (3.2 kilobase or kB) in length to Ginkgo Bioworks under their existing … Continued
Tarveda Therapeutics, Inc., a biopharmaceutical company discovering and developing Pentarins™ as a new class of potent and selective anti-cancer medicines, today announced that a Phase 1/2a clinical trial evaluating PEN-221 in patients with advanced neuroendocrine tumors and small cell lung … Continued
ARMO BioSciences, Inc., a clinical-stage immuno-oncology company, announced that the European Commission (EC) has granted the Company’s lead investigational immuno-oncology drug AM0010 (PEGylated Interleukin-10) Orphan designation for the treatment of pancreatic cancer. The EC’s approval follows a positive opinion in November … Continued
Muse bio today announced the publication of a paper in Nature Biotechnology describing, for the first time, its foundational technology platform that enables rational engineering of the whole genome with single-nucleotide precision. The technology, “CRISPR-enabled trackable genome engineering” (CREATE), has … Continued
Muse bio, a privately-held company leading the development of next-generation genome engineering technologies, today announced that Dr. Kevin Ness has been appointed Chief Executive Officer and member of the Board of Directors. Kevin succeeds Muse bio’s founding CEO Ryan Gill, … Continued
Spark Therapeutics (NASDAQ:ONCE) and Selecta Biosciences, Inc. (NASDAQ:SELB) today announced a license agreement that provides Spark Therapeutics with exclusive worldwide rights to Selecta’s proprietary Synthetic Vaccine Particles (SVP™) platform technology for co-administration with gene therapy targets, including FVIII for hemophilia A, as … Continued